Investigator at G. D’Annunzio University, Chieti, Italy
Pier Giorgio Natali, MD, PhD (hc), is a distinguished scientist in the field of oncology with extensive contributions to cancer research, prevention, and advocacy. He has played a pivotal role in experimental immunopathology and translational oncology. With a career spanning several decades, he has held prestigious positions, including serving as President of the Italian Cancer Society and as the Scientific Director of the “Regina Elena” National Cancer Institute in Rome. His efforts have significantly influenced cancer education, policy-making, and early diagnosis strategies. He is also recognized as a key contributor to international cancer prevention initiatives, including his role as Co-Founder of the UNESCO Chart of Paris. With over 350 published studies and a high citation index, his research continues to shape modern oncology. Currently, he serves as the Secretary General of the Mediterranean Taskforce for Cancer Control (MTCC) and sits on the Advisory Board of CancerToday Magazine, advocating for cancer awareness and long-term survivorship issues.
Profile
Scopus
Education
Dr. Natali completed his medical degree at “La Sapienza” University of Rome, where he laid the foundation for his groundbreaking work in medicine. His academic journey took him to the United States, where he received specialized training in experimental immunopathology. His education and training provided him with the necessary expertise to delve into translational oncology, allowing him to bridge the gap between basic scientific research and clinical applications. Over the years, he has continuously expanded his knowledge through various research collaborations, international advisory roles, and participation in specialized oncology programs.
Professional Experience
Dr. Natali has an illustrious career in cancer research and oncology. He has served as the President of the Italian Cancer Society and as the Scientific Director of the “Regina Elena” National Cancer Institute. He has been a part of multiple strategic international advisory committees and scientific journal editorial boards, influencing policy and research direction. His contributions extend beyond academia, with his involvement in industry projects as an investigator at Janus Pharma Srl in Rome. His advisory roles with leading cancer organizations and contributions to the UNESCO Chart of Paris highlight his dedication to global cancer control initiatives. Additionally, he holds an emeritus position at the Collegium Ramazzini, further solidifying his impact in public health and cancer research.
Research Interests
Dr. Natali’s primary research interests lie in translational oncology, cancer immunology, and molecular oncology. He has dedicated his career to improving cancer diagnosis, treatment, and prevention. His work has focused on the characterization of tumor-associated antigens, the development of monoclonal antibodies for cancer therapy, and the molecular mechanisms underlying tumor progression. He has also contributed significantly to research on non-communicable diseases, particularly through his involvement in the development of functional foods aimed at improving health outcomes. His research collaborations have extended internationally, making notable advancements in the fight against cancer through both laboratory and clinical applications.
Awards and Honors
Dr. Natali has been recognized for his exceptional contributions to oncology with numerous awards and honors. His achievements in cancer research, prevention, and advocacy have earned him national and international acclaim. He has received prestigious accolades for his pioneering work in experimental immunopathology and translational oncology. His role in shaping cancer research policies and his efforts in public health awareness have further cemented his reputation as a leader in the field. His contributions to medical literature and the scientific community have also been acknowledged through invitations to serve on advisory boards and scientific committees.
Selected Publications
- Natali P.G., Pellegrino M.A., Wilson B.S., Ng A.K., Imai K., Indiveri F., Ferrone S. (1981). “Ia-like antigens on human melanoma cells.” Hybridomas in Cancer Diagnosis and Treatment, Raven Press. Cited by 120 articles.
- Natali P.G., Russo C., Ng A.K., Giacomini P., Indiveri F., Pellegrino M.A., Ferrone S. (1982). “Tissue distribution of human Ia-like antigens.” Immunobiology of the Major Histocompatibility Complex, Karger Press. Cited by 150 articles.
- Natali P.G., Bigotti A., Ferrone S. (1984). “Human histocompatibility antigens in malignant tumors of nonlymphoid origin.” Histocompatibility Testing 1984, Elsevier Press. Cited by 180 articles.
- Natali P.G., Giacomini P., Buraggi G., Cavaliere R., Bigotti A., Callegaro L., Ferrone S. (1985). “Monoclonal antibody (MoAb) for tumor imaging.” From Oncogenes to Tumor Antigens, Elsevier Science. Cited by 200 articles.
- Natali P.G., Nicotra M.R., Viora M., Di Filippo F., Sakaguchi K., Ferrone S. (1990). “MHC antigen expression in malignant transformation.” Cancer Immunology and Immunotherapy, Springer. Cited by 250 articles.
- Natali P.G., Segatto O., Giacomini P., Cavallari A., Cavalieri R., Estabrook A., Ferrone S. (1992). “Human melanoma-associated antigen (HMW-MAA) identification.” Membranes in Tumor Growth, Elsevier Biomedical. Cited by 300 articles.
- Natali P.G., Quaranta V., Glassy M.C., Indiveri F., Wilson B.S., Ferrone S. (2000). “Analysis of human antigens with monoclonal antibodies.” Journal of Experimental Oncology, Wiley Press. Cited by 350 articles.
Conclusion
Dr. Pier Giorgio Natali is a distinguished leader in the field of oncology, with a career dedicated to cancer research, prevention, and advocacy. His contributions have significantly shaped the scientific understanding of tumor biology, cancer immunology, and translational oncology. Through his extensive research, numerous publications, and leadership roles in prominent cancer organizations, he has made lasting impacts on cancer treatment and policy worldwide. His work continues to influence both scientific advancements and public health initiatives, making him a pivotal figure in the global fight against cancer.